CNS Pharmaceuticals
CNSP
7 hedge funds and large institutions have $75.3K invested in CNS Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
250% more funds holding
Funds holding: 2 → 7 (+5)
0.03% less ownership
Funds ownership: 0.03% → 0% (-0.03%)
67% less capital invested
Capital invested by funds: $228K → $75.3K (-$153K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$97.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$85.8K |
| 3 |
VF
Virtu Financial
New York
|
+$58.8K |
| 4 |
Goldman Sachs
New York
|
+$13.5K |
| 5 |
Jane Street
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$223K |
| 2 |
Morgan Stanley
New York
|
-$3 |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $26.5K | +$97.2K | +339 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $23.8K | +$85.8K | +299 | +7,475% |
|
|
VF
3
Virtu Financial
New York
| $16K | +$58.8K | +205 | New |
|
|
4
Goldman Sachs
New York
| $3.68K | +$13.5K | +47 | New |
|
|
5
Jane Street
New York
| $3.02K | +$11.2K | +39 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $2.13K | +$7.75K | +27 | New |
|
|
APC
7
Aspire Private Capital
Cornelius,
North Carolina
| $52 | +$287 | +1 | New |
|
8
Bank of America
Charlotte,
North Carolina
| $30 | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $1 | – | – | – |
|
|
AFM
10
Anson Funds Management
Dallas,
Texas
| – | -$223K | -236 | Closed |
|
|
11
Fidelity Investments
Boston,
Massachusetts
| – | -$2 | – | – |
|
|
12
Morgan Stanley
New York
| – | -$3 | – | – |
|
CNSP Hedge Fund Activity: Q3 2024 in Review
7 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q3 2024, worth a combined $75.3K — down 67% from $228K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNSP positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $97.2K. The largest seller was Anson Funds Management, exiting entirely with an estimated $223K sold.
- 7 institutional investors held CNS Pharmaceuticals (CNSP) as of Q3 2024, up from 2 in Q2 2024.
- Funds reported $75.3K of CNS Pharmaceuticals stock for Q3 2024, down 67% quarter-over-quarter.
- 6 funds opened new CNS Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of +5 holders.
- The largest CNS Pharmaceuticals buyer in Q3 2024 was Geode Capital Management, an estimated $97.2K added.
- The largest CNS Pharmaceuticals seller in Q3 2024 was Anson Funds Management, an estimated $223K sold.
Based on aggregated 13F filings for Q3 2024.